Palifermin

CHEMBL1201821 Phase 4 Aprovado Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A recombinant human keratinocyte growth factor used to reduce the severity and duration of severe oral mucositis (mouth sores) in patients receiving high-dose chemotherapy with bone marrow transplantation. It stimulates the growth and repair of epithelial cells lining the mouth and gastrointestinal tract.

Áreas Terapêuticas

Mecanismo de Ação

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A recombinant human keratinocyte growth factor used to reduce the severity and duration of severe oral mucositis (mouth sores) in patients receiving high-dose chemotherapy with bone marrow transplantation. It stimulates the growth and repair of epithelial cells lining the mouth and gastrointestinal tract.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Palifermin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201821. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.